株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

双極性障害 (躁鬱病):パイプライン製品の分析

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232796
出版日 ページ情報 英文 122 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
双極性障害 (躁鬱病):パイプライン製品の分析 Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 122 Pages
概要

双極性障害は、以前は躁鬱病と呼ばれていました。情動障害 (すなわち気分障害) の一形態で、躁病または軽躁エピソードによって定義されます。症状は、食欲減退と体重減少/過食と体重増加、疲労、活力減退、ペースを落とす、不眠症、早朝覚醒/寝過ぎ、情動不安、神経過敏などです。素因として、年齢、ストレス、家族歴が挙げられます。治療には、抗けいれん薬、抗精神病薬、抗鬱薬などが含まれます。

当レポートでは、双極性障害 (躁鬱病) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

双極性障害 (躁鬱病) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

双極性障害 (躁鬱病):企業で開発中の治療薬

双極性障害 (躁鬱病):大学/機関で研究中の治療薬

双極性障害 (躁鬱病):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

双極性障害 (躁鬱病):企業で開発中の製品

双極性障害 (躁鬱病):大学/機関で研究中の製品

双極性障害 (躁鬱病) の治療薬開発に従事している企業

  • Aequus Pharmaceuticals Inc.
  • Amorsa Therapeutics Inc.
  • AstraZeneca Plc
  • Biogen, Inc.
  • D-Pharm Ltd.
  • Delpor, Inc.
  • Intas Pharmaceuticals Ltd.
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • KemPharm, Inc.
  • Mapi Pharma Ltd.
  • Navya Biologicals Pvt Ltd
  • Neurocrine Biosciences, Inc.
  • Omeros Corporation
  • 大塚ホールディングス
  • Pfizer Inc.
  • Reviva Pharmaceuticals Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • 大日本住友製薬
  • Zogenix, Inc.
  • Zysis Limited

双極性障害 (躁鬱病):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

双極性障害 (躁鬱病):最近のパイプライン動向

双極性障害 (躁鬱病):休止中のプロジェクト

双極性障害 (躁鬱病):開発が中止された製品

双極性障害 (躁鬱病):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8666IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline landscape.

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.Bipolar Disorder (Manic Depression).

Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bipolar Disorder (Manic Depression) Overview
  • Therapeutics Development
    • Pipeline Products for Bipolar Disorder (Manic Depression) - Overview
    • Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis
  • Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies
  • Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes
  • Bipolar Disorder (Manic Depression) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bipolar Disorder (Manic Depression) - Products under Development by Companies
  • Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes
  • Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development
    • Aequus Pharmaceuticals Inc.
    • Amorsa Therapeutics Inc.
    • AstraZeneca Plc
    • Biogen Inc
    • Delpor, Inc.
    • Intas Pharmaceuticals Ltd.
    • Intra-Cellular Therapies, Inc.
    • Johnson & Johnson
    • KemPharm, Inc.
    • Mapi Pharma Ltd.
    • Navya Biologicals Pvt Ltd
    • Neurocrine Biosciences Inc
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Reviva Pharmaceuticals Inc.
    • SK Biopharmaceuticals Co., Ltd.
    • Sumitomo Dainippon Pharma Co Ltd
    • Zogenix, Inc.
    • Zysis Limited
  • Bipolar Disorder (Manic Depression) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cycloserine + lurasidone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aripiprazole ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-1407 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-2803 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cenobamate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNV-1061436 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ebselen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Endoxifen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-18038683 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lurasidone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paliperidone palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGW-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • quetiapine fumarate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • risperidone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • risperidone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • risperidone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-5063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-PSY - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Bipolar Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Cancer and Neurodegenerative Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR50 for Bipolar Disorder and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target NMDA Receptor for Bipolar Depression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ziprasidone mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bipolar Disorder (Manic Depression) - Dormant Projects
  • Bipolar Disorder (Manic Depression) - Discontinued Products
  • Bipolar Disorder (Manic Depression) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia
      • Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office
      • Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
      • Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan
      • Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition
      • May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression
      • May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association
      • Feb 25, 2016: Intra-Cellular Therapies Provides Product Update
      • Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
      • Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression
      • Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder
      • Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
      • Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
      • Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder
      • May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016
  • Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Biogen Inc, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Mapi Pharma Ltd., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences Inc, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2016
  • Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2016
  • Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2016
  • Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H2 2016
  • Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016
  • Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top